42.37
price up icon0.36%   0.15
after-market Handel nachbörslich: 42.20 -0.17 -0.40%
loading

Exelixis Inc Aktie (EXEL) Neueste Nachrichten

pulisher
Jun 05, 2025

BofA Hikes Exelixis, Inc. (EXEL) Target Amid CRC Caution - Yahoo Finance

Jun 05, 2025
pulisher
Jun 05, 2025

Analyst Expectations For Exelixis's Future - Benzinga

Jun 05, 2025
pulisher
Jun 05, 2025

Exelixis (EXEL) Sees Price Target Raised by B of A Securities | EXEL Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

BofA Adjusts Price Target for Exelixis (EXEL) Amid Critical Pipe - GuruFocus

Jun 05, 2025
pulisher
Jun 04, 2025

Director Jack Wyszomierski Sells 7,535 Shares of Exelixis Inc (E - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Director Jack Wyszomierski Sells 7,535 Shares of Exelixis Inc (EXEL) - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Exelixis at Jefferies Conference: Strategic Moves for Growth By Investing.com - Investing.com Canada

Jun 04, 2025
pulisher
Jun 04, 2025

Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell? - sharewise

Jun 04, 2025
pulisher
Jun 04, 2025

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term - sharewise

Jun 04, 2025
pulisher
Jun 04, 2025

Transcript : Exelixis, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 07 - marketscreener.com

Jun 04, 2025
pulisher
Jun 03, 2025

Exelixis Stock Surges 28% YTD: Should You Buy Now Or Sell? - Barchart.com

Jun 03, 2025
pulisher
Jun 03, 2025

Exelixis at 45th Annual William Blair Conference: Oncology Ambitions - Investing.com Australia

Jun 03, 2025
pulisher
Jun 03, 2025

Transcript : Exelixis, Inc. Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 10 - marketscreener.com

Jun 03, 2025
pulisher
Jun 02, 2025

Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance

Jun 02, 2025
pulisher
Jun 02, 2025

Exelixis, Inc. (EXEL) Stock Analysis: Navigating Growth in the Biotech Space with Robust Revenue Momentum - DirectorsTalk Interviews

Jun 02, 2025
pulisher
May 30, 2025

2 Top Stocks to Buy With Less Than $100 - The Globe and Mail

May 30, 2025
pulisher
May 28, 2025

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - Yahoo Finance

May 28, 2025
pulisher
May 27, 2025

Transcript : Exelixis, Inc. Presents at TD Cowen's 6th Annual Oncology Innovation Summit, May-27-2025 02 - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Decreases Stake in Exelixis, Inc. (NASDAQ:EXEL) - Defense World

May 27, 2025
pulisher
May 25, 2025

EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort - MSN

May 25, 2025
pulisher
May 25, 2025

Exelixis’s SWOT analysis: stock poised for growth amid oncology pipeline progress By Investing.com - Investing.com South Africa

May 25, 2025
pulisher
May 25, 2025

Exelixis’s SWOT analysis: stock poised for growth amid oncology pipeline progress - Investing.com Australia

May 25, 2025
pulisher
May 25, 2025

Deutsche Bank AG Has $1.54 Million Stake in Exelixis, Inc. (NASDAQ:EXEL) - Defense World

May 25, 2025
pulisher
May 24, 2025

Insider Sell: Tomas Heyman Sells Shares of Exelixis Inc (EXEL) - GuruFocus

May 24, 2025
pulisher
May 23, 2025

3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL) - Yahoo Finance

May 23, 2025
pulisher
May 23, 2025

Earnings Estimates Moving Higher for Exelixis (EXEL): Time to Buy? - Yahoo Finance

May 23, 2025
pulisher
May 23, 2025

Exelixis (EXEL) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

May 23, 2025
pulisher
May 23, 2025

Solid Earnings Reflect Exelixis' (NASDAQ:EXEL) Strength As A Business - Yahoo Finance

May 23, 2025
pulisher
May 23, 2025

Product Performance, Big Money Lift Exelixis - Yahoo Finance

May 23, 2025
pulisher
May 23, 2025

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025 - BioSpace

May 23, 2025
pulisher
May 23, 2025

Exelixis reports promising kidney cancer trial results - Investing.com Australia

May 23, 2025
pulisher
May 23, 2025

Exelixis EVP Haley Patrick J. sells $1.5 million in stock By Investing.com - Investing.com Nigeria

May 23, 2025
pulisher
May 22, 2025

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-0 - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Exelixis EVP Haley Patrick J. sells $1.5 million in stock - Investing.com

May 22, 2025
pulisher
May 22, 2025

Exelixis Executives Engage in Significant Stock Transactions - TradingView

May 22, 2025
pulisher
May 22, 2025

Exelixis reports promising kidney cancer trial results By Investing.com - Investing.com India

May 22, 2025
pulisher
May 22, 2025

Exelixis (EXEL) Reports Promising Results from STELLAR-002 Renal Cancer Trial | EXEL Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025 | EXEL Stock N - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June | EXEL Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June - New Castle News

May 22, 2025
pulisher
May 22, 2025

Long Term Trading Analysis for (EXEL) - news.stocktradersdaily.com

May 22, 2025
pulisher
May 21, 2025

Exelixis (NasdaqGS:EXEL) Reports Robust Q1 2025 Earnings and Revenue Growth - Yahoo Finance

May 21, 2025
pulisher
May 20, 2025

Exelixis, Inc.: A Strategic Buy on Positive Momentum - marketscreener.com

May 20, 2025
pulisher
May 19, 2025

Exelixis (EXEL) is a Great Momentum Stock: Should You Buy? - Yahoo Finance

May 19, 2025
pulisher
May 19, 2025

Unlocking Exelixis (EXEL) International Revenues: Trends, Surprises, and Prospects - Yahoo Finance

May 19, 2025
$1.15
price down icon 0.86%
$580.59
price up icon 1.24%
$308.00
price up icon 0.88%
$36.54
price up icon 1.27%
$4.8111
price up icon 1.29%
$483.07
price down icon 0.38%
Kapitalisierung:     |  Volumen (24h):